Charlie Cook Email and Phone Number

• Lead a group of field-based medical science liaisons supporting Myfembree for heavy menstrual bleeding associated with uterine fibroids and management of moderate to severe pain associated with endometriosis

• Led a group of field-based medical science liaisons supporting Entyvio for the treatment of Crohn’s Disease and Ulcerative Colitis.• Revamped the insights process to be bring in more meaningful feedback, streamlined the monthly insights report and instituted a monthly live discussion of the insights.• Challenged the status quo to identify compliant ways to partner with commercial partners in the field.• Worked to revise the medical information process to be more efficient and enable great MSL involvement.• Defined MSL strategic objectives and alignment with medial affairs goals.• Provided input on MSL onboarding to ensure scientific training aligned with current state of the science.• Introduced medical excellence team to “Radical Candor” feedback approach and secured approval for virtual and live workshops.

• Led rapid expansion of MSL team from 2 MSLs to 49 MSLs & 6 Regional Directors on time (6 months) to support Phase 3 disease-modifying treatment (aducanumab)• Created a robust scientific and company onboarding process to ensure field readiness within 8 weeks• Defined strategic direction of MSL team and ensured alignment with Medical Affairs objectives and goals• Amplified cross-functional team efficiency by piloting combined KOL, MSL, and commercial account liaison meetings to assess site of care readiness • Developed MSL metrics and worked to create the infrastructure to support quantitative and qualitative assessment • Partnered with medical communications to develop high-value field resources • Developed a process to review and analyze medical insights from the field• Partnered with global learning to create continuous learning activities on scientific resources and identified knowledge gaps• Created plan for 7 MSLs from our partner company to be fully integrated into the field medical team; included scientific & medical strategy training and IT system access• Helped achieve centralized KOL engagement planning & tracking with a 360-degree view of HCP activities visible to all of medical• Led, inspired, and modeled collaborative teamwork resulting in personal and team accountability

• Led a rare disease field-based medical science liaison team of 7 supporting Spinraza, disease-modifying treatment for spinal muscular atrophy (SMA) • Credited with turning around team culture, morale, and engagement within 5 months• Reset expectations for personal and team accountability• Refined compliance guidelines for successful medical/commercial field partnership• Developed KOL engagement strategy to address the entry of 2 competitors • US field representative on National Plan of Action meeting committee• Instituted a novel process to collect and analyze field insights• Provided regular updates to internal stakeholders on MSL engagements and insights to drive strategy• Initiated KOL engagement strategy for Phase 3 ALS drug• Managed administrative responsibilities of team

• Charged with building a team of field-based medical science liaisons covering Alzheimer’s Disease• Created MSL strategy to align with medical affairs goals and objectives• Due to a negative futility analysis, the Phase 3 trial (aducanumab) was terminated and the team was reallocated to other therapeutic areas.

• Led a group of field-based medical science liaisons covering the entire Neuroscience portfolio from drug discovery to post-market • Transitioned team focus to neurology (Alzheimer's Disease, migraine headache, chronic pain) from psychiatry as portfolio evolved• Led launch of novel CGRP antibody treatment (Emgality) for migraine headache via effective cross-functional alignment/partnership with Medical and Commercial to ensure success• Drove a 75% increase in KOL touchpoints and a 66% increase in field productivity by creating strategic KOL engagement plans and collaborating with scientific communications to develop high-value KOL resources• Increased KOL engagement by 58% by driving synergy across MSL alliance partnership• Developed long-term MSL team strategy around KOL engagement, medical/commercial objectives, and medical resources • Created engagement strategy for support of marketed products and late phase/recently launched products.• MSL teams provided state formulary testimony in support of health outcomes group.• Partnered with key business partners in medical and commercial to ensure a successful launch • Experience with alliance partnerships

• Core team member who co-led a cross-functional team that conducted a nationwide deep dive into understanding the readiness and willingness of integrated health systems’ ability to detect, diagnose, and treat Alzheimer’s disease

• Acted as a liaison between external thought leaders/investigators who specialize in neuroscience and internal personnel to assist in medical information and research needs• Engaged KOLs/investigators in scientific information exchange supporting 3 products (Cymbalta, Zyprexa, Strattera) with multiple indications in depression, anxiety, schizophrenia, and ADHD• Supported pipeline assets and served as the MSL point of contact on the kappa opioid antagonist program (alcohol use disorders and depression).• Provided state formulary testimony• Served on various committees to improve operational efficiencies. • Attend neuroscience conferences to offer medical support for questions from external customers and to gather relevant scientific information for the company • Geography: Maryland, West Virginia, Western Pennsylvania

• Preclinical investigation of sex differences in chronic pain and opioid analgesia.• Earned NIH K12 award to support research• Conducted abuse liability testing in rats, mice and monkeys across various CNS mechanisms.• Taught pharmacology, behavioral neuroscience, drug abuse topics to graduate and medical students.